Contact through OTT webpage does not guarantee a second opinion visit at the site nor a slot in the specific clinical trial of interest.

Clinical trial details

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Identifier

CYC140-101

Sponsor

CYCLACEL BIOPHARMACEUTICALS INC.

Principal Investigator

ELENA GARRALDA CABANAS

Service

Oncology

Cohort for hematological patients available

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Targeted therapy
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: CYC140

Links

Clinical Trials GOV (NCT identifier): NCT05358379
EU Clinical Trials Register (eudraCT Identifier): 2022-000222-24